CARDIO-NOTES
Kanalga Telegram’da o‘tish
📈 Telegram kanali CARDIO-NOTES analitikasi
CARDIO-NOTES (@cardionotesposts) Arab til segmentidagi kanali faol ishtirokchi. Hozirda hamjamiyat 13 866 obunachidan iborat bo'lib, Tibbiyot toifasida 1 826-o'rinni va Misr mintaqasida 1 821-o'rinni egallagan.
📊 Auditoriya ko‘rsatkichlari va dinamika
невідомо sanasidan buyon loyiha tez o‘sib, 13 866 obunachiga ega bo‘ldi.
15 Sentabr, 2026 dagi oxirgi ma’lumotlarga ko‘ra kanal barqaror faollikka ega. Oxirgi 30 kunda obunachilar soni 2 478 ga, so‘nggi 24 soatda esa 0 ga o‘zgardi va umumiy qamrov yuqori darajada qolmoqda.
- Tasdiqlash holati: Tasdiqlanmagan
- Jalb etish (ER): Auditoriya o‘rtacha 91.97% darajada jalb etiladi. Nashrdan keyingi dastlabki 24 soatda kontent odatda umumiy obunachilar sonining N/A% ini tashkil etuvchi reaksiyalarni to‘playdi.
- Post qamrovi: Har bir post o‘rtacha 12 753 marta ko‘riladi; birinchi sutkada odatda 0 ta ko‘rish yig‘iladi.
- Reaksiyalar va o‘zaro ta’sir: Auditoriya faol: har bir postga o‘rtacha 61 ta reaksiya keladi.
- Tematik yo‘nalishlar: Kontent مَرِيض, ضَغط, عِلَاج, حَالَة, جُرعَة kabi asosiy mavzularga jamlangan.
📝 Tavsif va kontent siyosati
Muallif resursni shaxsiy fikrni ifoda etish maydoni sifatida ta’riflaydi:
“قناة خاصة بمنشورات طوارئ وعيادة القلب”
Yuqori yangilanish chastotasi (oxirgi ma’lumot 16 Sentabr, 2026 da olingan) sababli kanal doimo dolzarb va katta qamrovli bo‘lib qoladi. Analitika auditoriya kontent bilan faol hamkorlik qilishini, uni Tibbiyot toifasidagi muhim ta’sir nuqtasiga aylantirishini ko‘rsatadi.
13 866
Obunachilar
Ma'lumot yo'q24 soatlar
+127 kun
+2 47830 kun
Ma'lumot yuklanmoqda...
O'xshash kanallar
Taglar buluti
Kirish va chiqish esdaliklari
---
---
---
---
---
---
Obunachilarni jalb qilish
Sentabr '26
Sentabr '26
+104
0 kanalda
Avgust '26
+2 497
1 kanalda
Get PRO
Iyul '26
+40
0 kanalda
Get PRO
Iyun '26
+215
0 kanalda
Get PRO
May '26
+2 062
1 kanalda
Get PRO
Aprel '26
+68
0 kanalda
Get PRO
Mart '26
+1 394
1 kanalda
Get PRO
Fevral '26
+520
1 kanalda
Get PRO
Yanvar '26
+666
3 kanalda
Get PRO
Dekabr '25
+144
0 kanalda
Get PRO
Noyabr '25
+349
0 kanalda
Get PRO
Oktabr '25
+112
1 kanalda
Get PRO
Sentabr '25
+140
2 kanalda
Get PRO
Avgust '25
+624
5 kanalda
Get PRO
Iyul '25
+336
3 kanalda
Get PRO
Iyun '25
+632
2 kanalda
Get PRO
May '25
+436
0 kanalda
Get PRO
Aprel '25
+314
1 kanalda
Get PRO
Mart '25
+681
1 kanalda
Get PRO
Fevral '25
+221
2 kanalda
Get PRO
Yanvar '25
+636
2 kanalda
Get PRO
Dekabr '24
+274
0 kanalda
Get PRO
Noyabr '24
+552
0 kanalda
Get PRO
Oktabr '24
+66
0 kanalda
Get PRO
Sentabr '24
+1 152
0 kanalda
| Sana | Obunachilarni jalb qilish | Esdaliklar | Kanallar | |
| 16 Sentabr | 0 | |||
| 15 Sentabr | +1 | |||
| 14 Sentabr | +1 | |||
| 13 Sentabr | +1 | |||
| 12 Sentabr | +2 | |||
| 11 Sentabr | +5 | |||
| 10 Sentabr | +3 | |||
| 09 Sentabr | 0 | |||
| 08 Sentabr | 0 | |||
| 07 Sentabr | +7 | |||
| 06 Sentabr | 0 | |||
| 05 Sentabr | +10 | |||
| 04 Sentabr | +14 | |||
| 03 Sentabr | +15 | |||
| 02 Sentabr | +28 | |||
| 01 Sentabr | +17 |
Kanal postlari
| 2 | +3 ESC 2026 HF .pdf | 14 102 |
| 3 | 2026 ACC/ACC ECDP for management of HFpEF | 11 835 |
| 4 | ACC 2026 HFpEF .pdf | 11 799 |
| 5 | اختيار مضاد الصفائح في مرضى ال
ACS
النقطة الاولى
كل المرضى بياخذوا اسبرين (ما لم يكن ممنوع)
النقطة التانيه هنضيف واحد من ال
P2Y12 inhibitors
واحد من التلاته
Clopidogrel
Ticagrelor
Prasugrel
لو مريض ازمة قلبية، ACS و هيدخل قسطرة يبقى نضيف ال
Ticagrelor or prasugrel
يفضل عن ال
Clopidogrel
اللي هو البلافكس
ودا مبني على ال
PLATO trial
TRITON-TIMI 38 trial
اذا كان واحد من الاتنين مش متاح او ممنوع يتم استخدام البلافكس
مريض ال STEMI اللي بياخد مذيب بياخد في الاساس بلافكس (مش بريليك)
#cardionotes | 2 506 |
| 6 | Thromboembolism prophylaxis (e.g. with
LMWH) is recommended in acute HF patients not already anticoagulated and with no contraindication to anticoagulation.
#cardionotes | 1 973 |
| 7 | لو استخدمت
Triple antithrombotic therapy or dual antithrombotic therapy
وفيهم NOAC
اللي ممكن تقلل جرعته هو ال
Rivaroxaban or dabigatran
For both TAT and DAT regimens, the recommended doses for the NOACs are as follows: Apixaban 5 mg b.i.d., Dabigatran 110 mg or 150 mg b.i.d., Edoxaban
60 mg o.d., Rivaroxaban 15 mg or 20 mg o.d.
#cardionotes | 1 901 |
| 8 | Diabetes mellitus
Chronic kidney disease
Systemic lupus erythematosus
Rheumatoid arthritis
Hypothyroidism
دول اشهر الامراض اللي بترفع الدهون الثلاثية
#cardionotes | 1 757 |
| 9 | β-blockers, preferably non-selective β-blockers (nadolol or propranolol), are recommended in patients with Long QT Syndrome (LQTS) and documented QT interval prolongation to reduce the risk of arrhythmic events.
#cardionotes | 1 478 |
| 10 |  Matn yo'q... | 1 249 |
| 11 | The maximal daily dose for i.v. loop diuretics is generally considered to be:
* Furosemide: 400–600 mg/day (i.v.)
* Up to 1000 mg/day may be considered in patients with severely impaired kidney function.
#cardionotes | 1 238 |
| 12 | When AV surgery is indicated
Concomitant replacement of the aortic root or ascending aorta should be considered if the maximal diameter is ≥45 mm and the predicted surgical risk is low.
#cardionotes | 1 191 |
| 13 | In acute HF
Inotropes are administered under electrocardiographic monitoring and for a limited period of time due to their detrimental effects including myocardial ischaemia and arrhythmogenesis.In patients pre- treated with beta blockers, levosimendan or milrinone are the preferable inotropes, but in patients with systolic blood pressure below 85 mmHg, both agents should be avoided or used in combination with other inotropes or a vasopressor due to their hypotensive effects.
#cardionotes | 962 |
| 14 | Warfarin acts as a vitamin K antagonist (VKA) by inhibiting vitamin K epoxide reductase, thereby impairing the regeneration of active vitamin K and preventing γ-carboxylation of clotting factors II, VII, IX, and X, as well as proteins C and S.
#cardionotes | 759 |
| 15 | DOAC use in hepatic impairment
Child-Pugh class A: All DOACs appear to be safe.
Child-Pugh class B: Apixaban, dabigatran, and edoxaban can be used, and rivaroxaban should be avoided.
Child-Pugh class C: There is insufficient evidence to support the use of DOACs.
#cardionotes | 730 |
| 16 | All beta- blockers used for treatment of HF are lipophilic, with extensive liver metabolism. Lipid solubility allows these compounds to reside longer and at higher concentrations in cell membranes.
#cardionotes | 850 |
| 17 | الاسبرين يقي من تكرار ال VTE لكن بفاعلية اقل بكتير من ال
DOACs
Low-dose aspirin monotherapy provides modest benefit for secondary prevention of recurrent VTE after completion of anticoagulation, reducing recurrence risk by approximately 30% to 40%; however, it is substantially less effective than extended anticoagulation with DOACs.
#cardionotes | 889 |
| 18 | For most patients with acute VTE planned to receive a DOAC, apixaban should be considered as the treatment of choice
Source: 2026 ACC Scientific Statement; Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events.
#cardionotes | 657 |
| 19 | حالتين من ال
Pulmonary embolism
ممكن يتعالجوا في البيت (دون حجز بالمستشفى)
Subclinical PE
Symptomatic PE with a low clinical severity score.
#cardionotes | 652 |
| 20 |  Matn yo'q... | 629 |
